This page was compiled by Blockworks using publicly available information reviewed consistent with the TTF, possibly together with information supplied directly by the project where provided. Project-supplied information may correct, update, or supplement the public record, and may not be independently verifiable; Blockworks presents it as provided and does not verify or warrant its accuracy. Because this page depends on what has been disclosed, it may be incomplete — certain categories are more likely to include undisclosed items (e.g., non-announced fundraisings or material relationships), and the absence of an entry should not be read as confirmation that none exists.
Provide a concise narrative that clearly states each of (a)–(e) below.
Response
BIO Protocol operates decentralized science infrastructure that funds, launches, and sustains community-owned biotech research organizations called BioDAOs. It replaces closed institutional grant-making with community-led project selection, onchain fundraising, automatic market liquidity, milestone-linked funding, and standardized transparency for research projects.
(Source: Bio Protocol, BioDAOs)
BIO Protocol runs community-led project selection, fixed-price Ignition Sales for new launches, automatic post-sale liquidity formation, milestone-linked funding unlocks, treasury support drawn from secondary-market trading fees, and standardized transparency frameworks for project accountability.
(Source: Launcher, Bio Protocol V2)
The BIO stack combines a token launcher, BIO staking and vote-escrow mechanics, project-specific token launches, BioDAO governance, and automated DEX liquidity formation. New launches use fixed-price Ignition Sales, successful launches automatically seed BIO-paired liquidity pools, and ongoing project funding draws on fee flows tied to secondary-market activity.
(Source: Launcher, Launchpad Terms)
BIO holders stake BIO for governance and launch access, receive veBIO, vote on protocol upgrades and treasury meta-governance, earn BioXP for launch participation, provide the primary liquidity pair for launched tokens, access automated launch services, and receive ecosystem discounts.
(Source: Basic Token Information, Staking and veBIO)
Governance relies on BIO, vBIO, and veBIO mechanics. Staking BIO yields veBIO, which carries voting power and proposal rights. BIO and vBIO remain the governance tokens until veBIO reaches sufficient adoption and a formal governance proposal changes that structure.
(Source: Staking BIO, Basic Token Information)
For each existing entity: Labs/DevCo (e.g., Founder, CEO, CTO, COO), Foundation (e.g., President, Executive Director, CFO, COO), and DAO / onchain governance leadership (if applicable) list the: (a) full names, (b) official titles, (c) and prior experience of key team members. For any non-existent entity, explicitly mention it does not exist. External links may be included but they will not factor into the score.
Response
Full Name | Entity | Official Title | Prior Experience |
|---|---|---|---|
Paul Kohlhaas | Labs | Founder and CEO, BIO Protocol | Co-founder and CEO of Molecule and founding steward of VitaDAO. He built the DeSci funding stack that BIO spun out of and is a recognized leader in onchain biotech funding. |
Jose Pinto | Labs | Legal Counsel | Leads legal for BIO Protocol on the current public team roster. |
William Fang | Labs | Strategy | Leads strategy for BIO Protocol on the current public team roster. |
Bio.xyz Association issues the BIO token and serves as the not-for-profit legal steward of BIO infrastructure and treasury. The public record does not name individual Bio.xyz Association officers. | Foundation | ||
BIO governance runs through BIO, vBIO, and veBIO voting on Snapshot. The public record does not name individual DAO or Snapshot officeholders. | DAO | ||
Blockworks note: (Source: BIO Team, Paul Kohlhaas, Binance Labs Invests, Basic Token Information, Helpful Links, Staking and veBIO) |
Provide a structured description of the DAO's governance, powers, and economic rights. If a DAO does not exist, state so. Address the lettered items below. Even if there is no DAO, there must be an answer to (d).
Response
BIO Protocol does not publicly disclose a single protocol-level DAO IP registry, trademark holder, or legal-wrapper IP custodian. Public materials state that BioDAOs use Molecule's IP framework to own, license, and transact supported intellectual property at the project level.
(Source: BioDAOs, Basic Token Information)
BIO Protocol does not operate a standalone protocol-level DAO legal wrapper. Governance and admin powers run through token and platform mechanics. veBIO holders vote on governance proposals covering funding decisions, protocol upgrades, and parameter changes. The BIO token contract assigns DEFAULT_ADMIN_ROLE authority to manage roles and permanently enable transfers, the vesting contracts assign DEFAULT_ADMIN_ROLE authority over vesting schedules and VESTING_CREATOR_ROLE authority to create schedules, and official governance runs on Snapshot.
(Source: Staking and veBIO, Audits, Helpful Links)
Staking BIO yields veBIO, which represents governance power, voting rights, and a larger share of protocol rewards. Voting power increases with lock duration. veBIO votes on proposals, funding decisions, protocol upgrades, parameter changes, and meta-governance over treasury assets.
(Source: Staking and veBIO, Staking BIO, Basic Token Information)
BIO is the primary routing and liquidity asset for launched tokens. Platform documents describe a 1% fee on BIO/Token liquidity-pool trading split 70% to the project treasury and 30% to Bio.xyz for platform operations and ecosystem development. BIO holders do not hold a publicly disclosed direct right to receive protocol revenue distributions.
(Source: Bio Protocol, Launchpad Terms)
BIO Protocol does not publicly disclose a DAO dissolution or wind-up mechanism, vote threshold, or legal-wrapper board process at the protocol level.
(Source: Staking and veBIO, Helpful Links)
For the Primary Foundation do the following independently. If an entity does not exist, state that explicitly. Items (a)–(f) apply only if that entity exists; state explicitly that the entity doesn't exist. Definitions: The primary Foundation and DevCo can be explained as those entities which are directly involved in the issuance of the native token at launch.
Response
Bio.xyz Association issued the BIO token and operates as a Swiss not-for-profit organization that serves as legal steward of BIO infrastructure and treasury.
(Source: Basic Token Information, Bio Protocol on DeSci)
A 5% BIO allocation to Molecule funds the transfer of core IP, brand, and ecosystem stewardship to Bio.xyz Association. The public record does not disclose a full schedule of foundation-held repositories, trademarks, or subsidiaries.
(Source: Basic Token Information)
Bio.xyz Association stewards BIO infrastructure and treasury and operates the services under the platform terms. Bio.xyz defines, modifies, or discontinues BioXP earning methods, modifies lock duration and veBIO calculation methods, and operates the launcher and associated token-sale interfaces. The public record does not disclose a complete threshold-by-threshold foundation control matrix.
(Source: Basic Token Information, Launchpad Terms)
BIO Protocol does not publicly disclose a separate DevCo over which Bio.xyz Association exercises direct or indirect control.
(Source: Basic Token Information)
Bio.xyz Association operates the launcher, controls BioXP earning methods and expirations, and modifies staking lock duration, veBIO calculation methods, and associated privileges. The token and vesting contract documentation discloses DEFAULT_ADMIN_ROLE, MINTER_ROLE, TRANSFER_ROLE, and VESTING_CREATOR_ROLE. The public record does not attribute those roles to named individuals or wallets.
(Source: Launchpad Terms, Audits)
Bio.xyz receives a 30% share of the 1% BIO/Token liquidity-pool trading fee for platform operations and ecosystem development, plus the 5% BIO allocation that funds the transfer of core IP, brand, and ecosystem stewardship to Bio.xyz Association. The public record does not disclose equityholder-level or officer-level downstream distribution policies.
(Source: Launchpad Terms, Basic Token Information)
For the Primary DevCo do the following independently. If an entity does not exist, state that explicitly. Items (a)–(f) apply only if that entity exists; state explicitly that the entity doesn't exist. Definitions: The primary Foundation and DevCo can be explained as those entities which are directly involved in the issuance of the native token at launch.
Response
BIO Protocol does not operate a separate primary DevCo. The public record identifies Bio.xyz Association as the token issuer and legal steward and does not identify a separate issuer-side Labs or DevCo entity.
(Source: Basic Token Information)
BIO Protocol does not publicly disclose DevCo-specific IP ownership, trademarks, repositories, or subsidiaries because no separate primary DevCo exists in the public record.
(Source: Basic Token Information)
BIO Protocol does not publicly disclose a separate DevCo holding independent powers over DAO governance, treasury actions, or token administration.
(Source: Basic Token Information)
BIO Protocol does not publicly disclose a separate DevCo with direct or indirect control over Bio.xyz Association.
(Source: Basic Token Information)
BIO Protocol does not publicly attribute contract-admin roles to a separate DevCo entity.
(Source: Audits, Basic Token Information)
Public allocations cover Core Contributors, Advisors, Investors, Molecule, and the Molecule Ecosystem Fund. The public record does not identify a separate DevCo recipient entity behind those allocations.
(Source: Basic Token Information)
Disclose launch and initial supply details in a single initial allocation schedule covering the token's launch.
Response
BIO starting supply is 3,320,000,000 tokens. The token page distinguishes unlocked supply from circulating supply and does not publish one rolled-up single launch-date unlocked total across all buckets. (Source: Basic Token Information, Tokenomics)
BIO launched through a community-genesis fair-launch process rather than one fixed clearing price. The initial auction opened in August 2024, participants acquired BIO with ETH and other DeSci tokens, and the event ran 45 days or until BIO reached a 100 million dollar fully diluted valuation cap. (Source: Bio Protocol on DeSci, Basic Token Information)
The token trades under the ticker BIO. (Source: Basic Token Information, BIO Token)
BIO supply is uncapped. New BIO can be minted for future protocol or network growth, which requires deploying a new token contract to replace the current BIO token. (Source: Basic Token Information)
Address each of the following sub-items based on the project's airdrop status. If a sub-item does not apply to the project's situation, state that explicitly.
Response
Planned but not yet executed airdrop: Not applicable. BIO Protocol completed its TGE and executed the Community Airdrop. No pending or unexecuted initial TGE airdrop exists for which a forward-looking recipient wallet list commitment would apply. The bioDAOs and genesis-members tranche remains subject to an ongoing vesting schedule, but the allocation itself has been determined and distributed rather than left unexecuted.
Executed airdrop: BIO Protocol executed a Community Airdrop allocating 6% of total BIO supply, equal to 199,200,000 BIO.
Covered user segments: Ecosystem token holders, early BIO supporters from conception through launch, and core contributors from early ecosystem projects.
Allocation method: Not disclosed at the level of eligibility criteria or per-recipient weighting. BIO Protocol has published the tranche structure and vesting terms — the public airdrop tranche carries no vesting, and the bioDAOs and genesis-members tranche carries a 1-year cliff followed by a 6-year vest — but has not published the snapshot dates, qualifying thresholds, or formula used to size individual allocations within each segment.
Per-address source: None. BIO Protocol does not publish a per-address recipient file in the public record — no CSV/TSV/JSON allocation file, Dune table, full Merkle dump, GitHub repository embedding per-address allocations, or RPC endpoint exposing claim/amount data.
Sources: Basic Token Information, Staking BIO
No airdrop planned or conducted: Not applicable. BIO Protocol has conducted an airdrop, as described in (b).
Blockworks note: Sub-item (b) discloses the aggregate allocation size, covered segments, and per-tranche vesting terms. Two components remain undisclosed: the allocation methodology within each segment, and any wallet-level allocation source. The distinction between the two tranches — unvested public airdrop versus 1-year cliff plus 6-year vest for bioDAOs and genesis members — is disclosed in the token documentation, but the boundary between which recipients fall into which tranche is not defined in machine-readable form.
Projects must disclose all material terms of market-making arrangements that affect token liquidity. If the project has no agreements or deals with market makers, state that explicitly; doing so earns full credit. For each market maker, include in a table:
If the project has no agreements or deals with market makers, state that explicitly; doing so earns full credit. If no native tokens were loaned or allocated to market makers, state that explicitly; cash/fiat retainers or fees are not required for this item.
Response
Blockworks note: BIO Protocol does not publicly disclose BIO-specific market-maker agreements, token loans, or retained market-making structures. Public materials describe launcher, AMM, and liquidity-engine mechanics at the platform level and do not disclose BIO token market-maker counterparties or loan terms.
(Source: Launcher, Launchpad Terms)
Projects must disclose all material terms of centralized or decentralized exchange listings that affect token liquidity. For each listing, include in a table:
If the project has no agreements or deals with CEX or DEX, state that explicitly; doing so earns full credit; cash/fiat fee amounts are not required for this item.
Response
Blockworks note: BIO Protocol does not publicly disclose BIO-specific exchange listing agreements, DEX pool commitment schedules, or native-token listing fees. Public materials describe automatic liquidity-pool creation and AMM seeding in launcher mechanics and do not disclose issuer-side listing agreements for the BIO token itself.
(Source: Launcher, Launchpad Terms)
Disclose all prior token sales by the Project — including fundraising rounds, any material OTC sales to investors, and any discounted market-maker sales. For each sale, provide:
If no prior sales occurred, state that explicitly (e.g., "No prior fundraising, OTC, or discounted MM sales have occurred.").
Response
Blockworks note: (Source: Basic Token Information, Binance Labs (The Block), Binance Labs Press Release)
BIO raised funding through a community-genesis fair-launch process, an August 2024 initial auction, a November 2024 Binance Labs strategic investment, and a BIO Genesis event that raised over 33 million dollars by Q1 2025. Genesis backers include 1kx, Boost VC, and Northpond Ventures. BIO Protocol does not publish a complete instrument-level sale packet for every fundraising event.
(Source: Bio Protocol on DeSci, Binance Labs Invests, Bio Protocol)
If any, list prior exploits or incidents that directly affected the token, token supply, tokenholder balances, token contract, minting controls, burn mechanics, or custody of token supply. This question is not asking about general protocol, application, or smart contract exploits unless the incident directly affected the native token itself. If no prior incidents, state this explicitly (e.g., "No exploits affecting tokenholders or protocol funds as of YYYY-MM-DD").
Response
No exploit affecting tokenholders or protocol funds was identified in the public record as of April 22, 2026. The public security record consists of external audits indexed on the BIO docs site, including a Pashov Audit Group review of the Launchpad Curation Contracts dated March 12, 2025 and an FYEO review of the Launchpad v2 contracts. No exploited loss-of-funds incident affecting BIO holders or protocol funds appears in the public record.
(Source: Audits, Bio Security Review)
N/A
N/A
N/A
N/A
N/A
Describe material risk factors across the three categories below. Each category includes prompts to address at a minimum.
(a) Regulatory, Legal & Tax Risks — Describe how evolving laws and regulations could affect the project by answering, at a minimum, questions like:
Impact of Regulatory Change on TGE and Listings: (If applicable) How could evolving or conflicting laws and regulations affect your ability to complete the TGE, deliver tokens to purchasers, and list or maintain the token on trading venues in key jurisdictions?
Entity-Level Regulatory Impact: (If applicable) How could regulatory or legal changes impact your core entities (Foundation, DevCo, DAO, affiliated service providers), including enforcement actions, licensing requirements, or forced changes to structure or operations?
Tokenholder Tax Treatment: (If applicable) What uncertainties exist around how tokenholders may be taxed, and make clear that tokenholders are responsible for understanding their own tax obligations?
Jurisdictional & User Access Restrictions: (If applicable) If the project restricts access for certain jurisdictions or user types (e.g., U.S. persons, sanctioned countries, retail vs. professional), what are those restrictions and what risks do they create for users and for the project?
(b) Protocol, Technology & Security Risks — Describe risks to network and contract reliability, correctness, and safety by answering, at a minimum, questions like:
Bugs and Design Flaws: (If applicable) What bugs, design flaws, or implementation errors could exist in your core protocol code, smart contracts, and any bridges, rollups, or oracles that you depend on, and how could these lead to loss of funds or disruption of the protocol?
Security Measures & Their Limitations: (If applicable) What security measures have you taken (audits, formal verification, bug bounties), and what types of failures might these measures still fail to detect or prevent?
(c) Token Economics, Unlocks & Incentive Risks — Describe how the token's economic design and supply schedule could affect holders by answering, at a minimum, questions like:
Critical Economic Assumptions: (If applicable) Which economic assumptions (e.g., staking yields, fee revenue, liquidity incentives, MEV capture, demand for blockspace) are critical for protocol security, utility, and governance, and what happens if those assumptions fail?
Governance Control over Monetary Policy & Rewards: (If applicable) To what extent can governance change monetary policy, fee parameters, or reward allocations (e.g., inflation rate, treasury flows, incentive programs), and how could such changes adversely affect tokenholders?
Response
Impact of Regulatory Change on TGE and Listings
Regulatory change affects launch access, token-sale mechanics, and venue availability because Bio.xyz Association operates the services, requires users to rely on third-party wallets, and governs launch access through platform terms and promoter agreements rather than custodial intermediation. Changes in securities, token-sale, sanctions, or market-structure rules force changes to launch eligibility, platform operations, or venue support.
(Source: Launchpad Terms)
Entity-Level Regulatory Impact
Bio.xyz Association issues BIO, stewards BIO infrastructure and treasury, and operates the services. That role carries entity-level exposure to legal changes affecting token-launch platforms, operational disclosures, sanctions screening, and permitted product scope.
(Source: Basic Token Information, Launchpad Terms)
Tokenholder Tax Treatment
BIO terms place legal and tax compliance on users, and the airdrop and genesis terms require participants to assume their own tax consequences. Tokenholders carry uncertainty around local tax treatment of staking, airdrops, launch participation, and secondary-market activity.
(Source: Launchpad Terms)
Jurisdictional & User Access Restrictions
The genesis and airdrop terms impose eligibility restrictions and jurisdictional controls. Changes in law expand those restrictions, limit user access, or require additional compliance gating for launch participation and token distribution.
(Source: Launchpad Terms)
Bugs and Design Flaws
The Pashov Audit Group review of the Launchpad Curation Contracts, dated March 12, 2025, reported one critical, two high, two medium, and three low findings. The findings include an incorrect vestingDuration parameter flow, a pledge-limit bypass risk for whitelisted users, a potential permanent denial of service on updateFundraiser(), precision issues in token distribution math, and whitelist-allocation edge cases. Contract-level design or implementation errors of this kind affect vesting, allocation fairness, or fundraiser operation when they reach production.
(Source: Bio Security Review, Audits)
Security Measures & Their Limitations
BIO indexes multiple external security reviews on the docs site, including Pashov Audit Group and FYEO reviews. The audit reports state that security reviews cannot guarantee the complete absence of vulnerabilities and recommend further reviews, bug bounties, and monitoring.
(Source: Audits, Bio Security Review)
Critical Economic Assumptions
BIO economics depend on continued demand for launches, staking, BioXP participation, and secondary-market trading. The liquidity engine ties ongoing project funding to AMM trading fees and milestone-linked unlocks, and the token page ties governance participation and launch access to BIO staking. Weakening demand reduces fee-driven funding, liquidity depth, and governance participation.
(Source: Launcher, Basic Token Information, Staking BIO)
Governance Control over Monetary Policy & Rewards
BIO supply is uncapped, the token page states the initial distribution changes over time through future governance proposals, and platform terms let Bio.xyz modify BioXP earning methods, expirations, lock durations, veBIO calculation methods, and associated privileges. Those powers reshape participation economics, governance weight, and tokenholder expectations over time.
(Source: Basic Token Information, Launchpad Terms, BioXP)
This Token Transparency Filing is provided for general informational purposes only and does not verify or warrant the accuracy of individual answers.
